<DOC>
	<DOC>NCT01051037</DOC>
	<brief_summary>The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically confirmed primary lung cancer, lung metastasis from another primary, or recurrent tumors in the setting of prior RFA or cryotherapy Tumors &lt; 2 cm from trachea or zone of proximal bronchial tree (central tumors) Each tumor &lt; 5 cm in size prior to treatment Medically inoperable patients as determined at the multidisciplinary thoracic tumor board, or medically operable patients who refuse surgery Criterion for medical inoperability include: Overall clinical assessment at the UCLA thoracic tumor board Reduced Pulmonary Function (FEV1, DLCO, etc) based on one major or two minor criterion as described below: Modified ACOSOG Criteria for medical inoperability: Major Criteria: FEV1% &lt; 50% or &lt; 1L and DLCO &lt; 50% Minor Criteria: Age &gt; 75, FEV1 5160% predicted, or FEV1 11.2L, DLCO 51%60% predicted, pulmonary hypertension, poor left ventricular function (EF &lt; 40% or less), resting or exercise arterial pO2 &lt; 55 mmHg, and pCO2 &gt; 45 mmHg Age &gt; 18 years old KPS &gt; 70 If a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented. Ability to understand and the willingness to sign a written informed consent Prior thoracic radiation near the targets of interest More than 2 central tumor targets per patient Active infections requiring systemic antibiotics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>lung tumors</keyword>
	<keyword>central airways</keyword>
</DOC>